STMicroelectronics announces timing for third quarter 2026 earnings release and conference call

Geneva – October 5, 2026 – STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, announced that it will release third quarter 2026 earnings before the opening of trading on the European Stock Exchanges on October 29, 2026.

The press release will be available immediately after the release on the Company’s website at www.st.com.

STMicroelectronics will conduct a conference call with analysts, investors and reporters to discuss its third quarter 2026 financial results and current business outlook on October 29, 2026 at 9:30 a.m. Central European Time (CET) / 4:30 a.m. U.S. Eastern Time (ET).

A live webcast (listen-only mode) of the conference call will be accessible at ST’s website, https://investors.st.com, and will be available for replay until November 13, 2026.

About STMicroelectronics
At ST, we are 49,000 creators and makers of semiconductor technologies mastering the semiconductor supply chain with state-of-the-art manufacturing facilities. An integrated device manufacturer, we work with more than 200,000 customers and thousands of partners to design and build products, solutions, and ecosystems that address their challenges and opportunities, and the need to support a more sustainable world. Our technologies enable smarter mobility, more efficient power and energy management, and the wide-scale deployment of cloud-connected autonomous things. We are on track to be carbon neutral in all direct and indirect emissions (scopes 1 and 2), product transportation, business travel, and employee commuting emissions (our scope 3 focus), and to achieve our 100% renewable electricity sourcing goal by the end of 2027. Further information can be found at www.st.com   

For more information, please contact:

INVESTOR RELATIONS
Jérôme Ramel
EVP Corporate Development & Integrated External Communication
Tel: +41.22.929.59.20
jerome.ramel@st.com    
  
MEDIA RELATIONS
Alexis Breton
Group VP Corporate External Communications
Tel: +33.6.59.16.79.08
alexis.breton@st.com

Attachment

STMicroelectronics announces timing for third quarter 2026 earnings release and conference call

Geneva – October 5, 2026 – STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, announced that it will release third quarter 2026 earnings before the opening of trading on the European Stock Exchanges on October 29, 2026.

The press release will be available immediately after the release on the Company’s website at www.st.com.

STMicroelectronics will conduct a conference call with analysts, investors and reporters to discuss its third quarter 2026 financial results and current business outlook on October 29, 2026 at 9:30 a.m. Central European Time (CET) / 4:30 a.m. U.S. Eastern Time (ET).

A live webcast (listen-only mode) of the conference call will be accessible at ST’s website, https://investors.st.com, and will be available for replay until November 13, 2026.

About STMicroelectronics
At ST, we are 49,000 creators and makers of semiconductor technologies mastering the semiconductor supply chain with state-of-the-art manufacturing facilities. An integrated device manufacturer, we work with more than 200,000 customers and thousands of partners to design and build products, solutions, and ecosystems that address their challenges and opportunities, and the need to support a more sustainable world. Our technologies enable smarter mobility, more efficient power and energy management, and the wide-scale deployment of cloud-connected autonomous things. We are on track to be carbon neutral in all direct and indirect emissions (scopes 1 and 2), product transportation, business travel, and employee commuting emissions (our scope 3 focus), and to achieve our 100% renewable electricity sourcing goal by the end of 2027. Further information can be found at www.st.com   

For more information, please contact:

INVESTOR RELATIONS
Jérôme Ramel
EVP Corporate Development & Integrated External Communication
Tel: +41.22.929.59.20
jerome.ramel@st.com    
  
MEDIA RELATIONS
Alexis Breton
Group VP Corporate External Communications
Tel: +33.6.59.16.79.08
alexis.breton@st.com

Attachment

In September 2026, AS Tallink Grupp transported 405,069 passengers, representing a 4.5% increase compared to September 2025. The number of cargo units increased by 10.0% to 23,386 units, while the number of passenger vehicles increased by 0.1% to 56,010 units compared to the same period a year ago.

In the third quarter of the year (July–September) AS Tallink Grupp transported 1,816,174 passengers, representing a 2.8% increase compared to the same period in 2025. The number of transported cargo units increased by 7.8% to 64,980 units and the number of passenger vehicles decreased by 1.1% to 249,100 units compared to the same period a year ago.

AS Tallink Grupp passenger, cargo unit and passenger vehicle volumes for September 2026 and the third quarter of the year were as follows:

  Sept 2026 Sept 2025 Change Q3 2026 Q3 2025 Change
Passengers 405,069 387,482 4.5% 1,816,174 1,766,335 2.8%
Estonia – Finland 281,012 261,530 7.4% 1,183,760 1,166,278 1.5%
Finland – Sweden 92,464 88,933 4.0% 458,650 435,770 5.3%
Estonia – Sweden 31,593 37,019 -14.7% 173,764 164,287 5.8%
             
Cargo Units 23,386 21,269 10.0% 64,980 60,306 7.8%
Estonia – Finland 18,350 15,338 19.6% 51,467 44,388 15.9%
Finland – Sweden 3,578 2,882 24.1% 9,510 7,891 20.5%
Estonia – Sweden 1,458 3,049 -52.2% 4,003 8,027 -50.1%
             
Passenger Vehicles 56,010 55,973 0.1% 249,100 251,751 -1.1%
Estonia – Finland 48,945 48,947 0.0% 203,274 208,228 -2.4%
Finland – Sweden 5,346 4,817 11.0% 32,512 30,107 8.0%
Estonia – Sweden 1,719 2,209 -22.2% 13,314 13,416 -0.8%

ESTONIA – FINLAND
The third quarter results for the Estonia-Finland route reflect the operations of the shuttle vessels MyStar and Megastar and the cruise ferry Victoria I.

FINLAND – SWEDEN
The third quarter results for the Finland-Sweden routes reflect the operations of the Helsinki-Stockholm route (the cruise ferries Silja Serenade and Silja Symphony) and the Turku-Stockholm route (the cruise ferry Baltic Princess). The cruise ferry Baltic Princess did not operate the Turku-Stockholm route for two days in September due to scheduled maintenance works.

ESTONIA – SWEDEN
The third quarter results for the Estonia-Sweden route reflect the operations of the cruise ferries Baltic Queen and Romantika on the Tallinn-Stockholm route, with Romantika operating on the route in July and for three days in August.

A year ago, the Estonia-Sweden routes were operated by the cruise ferry Baltic Queen on the Tallinn-Stockholm route and Superfast IX on the Paldiski-Kapellskär route. Following the commencement of the charter agreement for the passenger vessel Superfast IX on 1 May 2026, operations on the Paldiski-Kapellskär route have been ceased.

Anneli Simm
Investor Relations Manager

AS Tallink Grupp
Sadama 5
10111 Tallinn, Estonia
E-mail anneli.simm@tallink.ee
Phone: +372 5615 7170

Attachment

In September 2026, AS Tallink Grupp transported 405,069 passengers, representing a 4.5% increase compared to September 2025. The number of cargo units increased by 10.0% to 23,386 units, while the number of passenger vehicles increased by 0.1% to 56,010 units compared to the same period a year ago.

In the third quarter of the year (July–September) AS Tallink Grupp transported 1,816,174 passengers, representing a 2.8% increase compared to the same period in 2025. The number of transported cargo units increased by 7.8% to 64,980 units and the number of passenger vehicles decreased by 1.1% to 249,100 units compared to the same period a year ago.

AS Tallink Grupp passenger, cargo unit and passenger vehicle volumes for September 2026 and the third quarter of the year were as follows:

  Sept 2026 Sept 2025 Change Q3 2026 Q3 2025 Change
Passengers 405,069 387,482 4.5% 1,816,174 1,766,335 2.8%
Estonia – Finland 281,012 261,530 7.4% 1,183,760 1,166,278 1.5%
Finland – Sweden 92,464 88,933 4.0% 458,650 435,770 5.3%
Estonia – Sweden 31,593 37,019 -14.7% 173,764 164,287 5.8%
             
Cargo Units 23,386 21,269 10.0% 64,980 60,306 7.8%
Estonia – Finland 18,350 15,338 19.6% 51,467 44,388 15.9%
Finland – Sweden 3,578 2,882 24.1% 9,510 7,891 20.5%
Estonia – Sweden 1,458 3,049 -52.2% 4,003 8,027 -50.1%
             
Passenger Vehicles 56,010 55,973 0.1% 249,100 251,751 -1.1%
Estonia – Finland 48,945 48,947 0.0% 203,274 208,228 -2.4%
Finland – Sweden 5,346 4,817 11.0% 32,512 30,107 8.0%
Estonia – Sweden 1,719 2,209 -22.2% 13,314 13,416 -0.8%

ESTONIA – FINLAND
The third quarter results for the Estonia-Finland route reflect the operations of the shuttle vessels MyStar and Megastar and the cruise ferry Victoria I.

FINLAND – SWEDEN
The third quarter results for the Finland-Sweden routes reflect the operations of the Helsinki-Stockholm route (the cruise ferries Silja Serenade and Silja Symphony) and the Turku-Stockholm route (the cruise ferry Baltic Princess). The cruise ferry Baltic Princess did not operate the Turku-Stockholm route for two days in September due to scheduled maintenance works.

ESTONIA – SWEDEN
The third quarter results for the Estonia-Sweden route reflect the operations of the cruise ferries Baltic Queen and Romantika on the Tallinn-Stockholm route, with Romantika operating on the route in July and for three days in August.

A year ago, the Estonia-Sweden routes were operated by the cruise ferry Baltic Queen on the Tallinn-Stockholm route and Superfast IX on the Paldiski-Kapellskär route. Following the commencement of the charter agreement for the passenger vessel Superfast IX on 1 May 2026, operations on the Paldiski-Kapellskär route have been ceased.

Anneli Simm
Investor Relations Manager

AS Tallink Grupp
Sadama 5
10111 Tallinn, Estonia
E-mail anneli.simm@tallink.ee
Phone: +372 5615 7170

Attachment

Strasbourg, France, October 5, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a poster highlighting preclinical data with PoxSTG-EEV, a novel enveloped oncolytic virus designed for systemic delivery, at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting.
SITC 2026 will take place November 4 – 8, 2026, in Phoenix, Arizona (USA).

Poster details

Title: “PoxSTG-EEV: a Novel Enveloped Virion–Based Formulation of a Chimeric Oncolytic PoxVirus Adapted for Systemic Delivery”

  • Abstract number: 1050
  • Date: November 7, 2026
  • Authors: Johann Foloppe, Juliette Kempf, Michèle Klein, Julie Hortelano, Baptiste Moreau, Laurine Gault, Isabelle Farine, Philippe Erbs

The abstract will be available on the SITC website on November 3, 2026, at 9 a.m. ET

***

Contacts

Transgene:  
Media: Investors & Analysts:
Caroline Tosch-Pourchot Lucie Larguier
Corporate and Scientific Communications Manager Chief Financial Officer (CFO)
+33 (0)3 68 33 27 38 +33 (0)3 88 27 91 00/21
communication@transgene.fr investorrelations@transgene.fr
MEDiSTRAVA  
Frazer Hall/Sylvie Berrebi  
+ 44 (0)203 928 6900  
transgene@medistrava.com  


About Transgene
Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing virus-based targeted immunotherapies and vaccines. The Company’s clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. Transgene’s myvac® platform is designed to develop individualized neoantigen therapeutic vaccines (INTVs), with potential across multiple solid tumor types.
TG4050, the first INTV based on the myvac® platform is the Company’s lead asset, with demonstrated clinical proof of principle in the adjuvant treatment of head and neck cancer. TG4070, the second myvac®-based INTV introduces Transgene’s proprietary AI-driven neoantigen selection and scalable cell-line manufacturing capabilities and is in Phase 1 clinical development in combination with nivolumab in the adjuvant treatment of non-small cell lung cancer (NSCLC). The Company’s other viral vector-based assets include BT-001, an oncolytic virus based on the Invir.IO® viral backbone, which is in clinical development. Transgene also conducts innovative discovery and preclinical work, aimed at developing novel viral vector-based modalities.
With Transgene’s myvac® platform, therapeutic vaccination enters the field of precision medicine with an immunotherapy tailored to each individual patient. The myvac® approach enables the generation of virus-based immunotherapies encoding patient-specific neoantigens. Transgene has further expanded the platform’s capabilities with its own proprietary AI-driven neoantigen selection and scalable cell-line manufacturing.
Leveraging its MVA and cell-line manufacturing expertise, Transgene is developing TG-MVA™, a next-generation prophylactic vaccine candidate against mpox and smallpox designed to address key manufacturing and supply challenges.
Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.
Additional information about Transgene is available at: www.transgene.com
Follow us on social media: LinkedIn: @Transgene — X: @TransgeneSA — Bluesky: @Transgene

Disclaimer
This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company’s activities, perspectives, financial situation, results, regulatory authorities’ agreement with development phases, and development. The Company’s ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document, available on the AMF website (http://www.amf-france.org) or on Transgene’s website (www.transgene.com). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

Attachment

Strasbourg, France, October 5, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a poster highlighting preclinical data with PoxSTG-EEV, a novel enveloped oncolytic virus designed for systemic delivery, at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting.
SITC 2026 will take place November 4 – 8, 2026, in Phoenix, Arizona (USA).

Poster details

Title: “PoxSTG-EEV: a Novel Enveloped Virion–Based Formulation of a Chimeric Oncolytic PoxVirus Adapted for Systemic Delivery”

  • Abstract number: 1050
  • Date: November 7, 2026
  • Authors: Johann Foloppe, Juliette Kempf, Michèle Klein, Julie Hortelano, Baptiste Moreau, Laurine Gault, Isabelle Farine, Philippe Erbs

The abstract will be available on the SITC website on November 3, 2026, at 9 a.m. ET

***

Contacts

Transgene:  
Media: Investors & Analysts:
Caroline Tosch-Pourchot Lucie Larguier
Corporate and Scientific Communications Manager Chief Financial Officer (CFO)
+33 (0)3 68 33 27 38 +33 (0)3 88 27 91 00/21
communication@transgene.fr investorrelations@transgene.fr
MEDiSTRAVA  
Frazer Hall/Sylvie Berrebi  
+ 44 (0)203 928 6900  
transgene@medistrava.com  


About Transgene
Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing virus-based targeted immunotherapies and vaccines. The Company’s clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. Transgene’s myvac® platform is designed to develop individualized neoantigen therapeutic vaccines (INTVs), with potential across multiple solid tumor types.
TG4050, the first INTV based on the myvac® platform is the Company’s lead asset, with demonstrated clinical proof of principle in the adjuvant treatment of head and neck cancer. TG4070, the second myvac®-based INTV introduces Transgene’s proprietary AI-driven neoantigen selection and scalable cell-line manufacturing capabilities and is in Phase 1 clinical development in combination with nivolumab in the adjuvant treatment of non-small cell lung cancer (NSCLC). The Company’s other viral vector-based assets include BT-001, an oncolytic virus based on the Invir.IO® viral backbone, which is in clinical development. Transgene also conducts innovative discovery and preclinical work, aimed at developing novel viral vector-based modalities.
With Transgene’s myvac® platform, therapeutic vaccination enters the field of precision medicine with an immunotherapy tailored to each individual patient. The myvac® approach enables the generation of virus-based immunotherapies encoding patient-specific neoantigens. Transgene has further expanded the platform’s capabilities with its own proprietary AI-driven neoantigen selection and scalable cell-line manufacturing.
Leveraging its MVA and cell-line manufacturing expertise, Transgene is developing TG-MVA™, a next-generation prophylactic vaccine candidate against mpox and smallpox designed to address key manufacturing and supply challenges.
Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.
Additional information about Transgene is available at: www.transgene.com
Follow us on social media: LinkedIn: @Transgene — X: @TransgeneSA — Bluesky: @Transgene

Disclaimer
This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company’s activities, perspectives, financial situation, results, regulatory authorities’ agreement with development phases, and development. The Company’s ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document, available on the AMF website (http://www.amf-france.org) or on Transgene’s website (www.transgene.com). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

Attachment

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS

Neuberger Private Equity Partners Announces Transaction in Own Shares

St Peter Port, Guernsey 5 October 2026

Neuberger Private Equity Partners Limited (“NBPE” or the “Company”) today announces details of Class A Shares bought back pursuant to general authority granted by shareholders of the Company on 11 June 2026 and the share buy-back agreement with Jefferies International Limited.

Transaction on London Stock Exchange

Date of purchase of Shares 2 October 2026
Number of Shares purchased 25,223 Class A Shares
Highest price/lowest price paid £14.96 / £14.79
ISIN for the Shares GG00B1ZBD492

All Class A Shares bought back will be cancelled. Following the cancellation, the number of outstanding Class A Shares is 37,502,593‬. The Company also has 3,150,408 Class A shares held in treasury. For reporting purposes under the FCA’s Disclosure Guidance and Transparency Rules the market should use the figure of 37,502,593 voting rights when determining if they are required to notify their interest in, or a change to their interest in the Company.

For further information, please contact:

NBPE Investor Relations        +44 20 3214 9002
Luke Mason        NBPrivateMarketsIR@nb.com

Oak Group        +44 1481 723450

        NBPEP@oak.group

About Neuberger Private Equity Partners Limited

Neuberger Private Equity Partners Limited (“NBPE”) invests in direct private equity investments alongside market leading private equity firms globally. NB Alternatives Advisers LLC (the “Investment Manager”), an indirect wholly owned subsidiary of Neuberger Berman Group LLC, is responsible for sourcing, execution and management of NBPE. The vast majority of direct investments are made with no management fee / no carried interest payable to third-party GPs, offering greater fee efficiency than other listed private equity companies. NBPE seeks capital appreciation through growth in net asset value over time while paying a bi-annual dividend.

LEI number: 213800UJH93NH8IOFQ77

About Neuberger

Neuberger was founded in 1939 to do one thing: deliver compelling investment results for our clients over the long term. This remains our singular purpose today, driven by a culture rooted in deep fundamental research, the pursuit of investment insight and continuous innovation on behalf of clients, and facilitated by the free exchange of ideas across the organization.

From offices in 39 cities[1] across 26 countries, Neuberger manages a range of equity, fixed income, private equity and hedge fund strategies on behalf of institutions, advisors and individual investors worldwide. With more than 780[1] investment professionals and over 2,900[1] employees in total, Neuberger has built a diverse team of individuals united in their commitment to client outcomes and investment excellence. Our culture has afforded us enviable retention rates among our senior investment staff and we are proud to have been ranked 1st by Pensions & Investments in their 2025 “Best Places to Work in Money Management” survey, where we have placed 1st in four of the last five years and finished in the top two for 12 consecutive years[2].

As a private, independent, employee-owned investment manager, Neuberger is structurally aligned with the long-term interests of our clients. We have no external parent or public shareholders to serve, nor other lines of business to distract us from our core mission. And with our employees and their families invested alongside our clients—plus 100% of employee deferred cash compensation directly linked to team and firm strategies—we are truly in this together.
For more information, please visit our website: www.nb.com/en/global/who-we-are.

Media Contacts:
US: Soogyung Jordan: Soogyung.Jordan@nb.com
EMEA: Fiona Kehily: Fiona.Kehily@nb.com

[1] Firm data reflects the collective data for the various subsidiaries of Neuberger Berman Group LLC as of 30 June 2026.

[2] Among organizations with over 1,000 employees by Pensions & Investments. For additional information on the criteria for the award, please visit https://www.pionline.com/awards/best-places-to-work-in-money-management/pi-best-places-to-work-2025.

This material is issued on a limited basis through various global subsidiaries and affiliates of Neuberger Berman Group LLC. Please visit www.nb.com/disclosure-global-communications to learn about each company and the legal restrictions and restrictions. The name “Neuberger Berman” and logo are registered service marks of Neuberger Berman Group LLC.

© 2026 Neuberger Berman Group LLC. All rights reserved.

This press release appears as a matter of record only and does not constitute an offer to sell or a solicitation of an offer to purchase any security.

NBPE is established as a closed-end investment company domiciled in Guernsey. NBPE has received the necessary consent of the Guernsey Financial Services Commission. The value of investments may fluctuate. Results achieved in the past are no guarantee of future results. This document is not intended to constitute legal, tax or accounting advice or investment recommendations. Prospective investors are advised to seek expert legal, financial, tax and other professional advice before making any investment decision. Statements contained in this document that are not historical facts are based on current expectations, estimates, projections, opinions and beliefs of NBPE’s investment manager. Such statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon. Additionally, this document contains “forward-looking statements.” Actual events or results or the actual performance of NBPE may differ materially from those reflected or contemplated in such targets or forward-looking statements.

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS

Neuberger Private Equity Partners Announces Transaction in Own Shares

St Peter Port, Guernsey 5 October 2026

Neuberger Private Equity Partners Limited (“NBPE” or the “Company”) today announces details of Class A Shares bought back pursuant to general authority granted by shareholders of the Company on 11 June 2026 and the share buy-back agreement with Jefferies International Limited.

Transaction on London Stock Exchange

Date of purchase of Shares 2 October 2026
Number of Shares purchased 25,223 Class A Shares
Highest price/lowest price paid £14.96 / £14.79
ISIN for the Shares GG00B1ZBD492

All Class A Shares bought back will be cancelled. Following the cancellation, the number of outstanding Class A Shares is 37,502,593‬. The Company also has 3,150,408 Class A shares held in treasury. For reporting purposes under the FCA’s Disclosure Guidance and Transparency Rules the market should use the figure of 37,502,593 voting rights when determining if they are required to notify their interest in, or a change to their interest in the Company.

For further information, please contact:

NBPE Investor Relations        +44 20 3214 9002
Luke Mason        NBPrivateMarketsIR@nb.com

Oak Group        +44 1481 723450

        NBPEP@oak.group

About Neuberger Private Equity Partners Limited

Neuberger Private Equity Partners Limited (“NBPE”) invests in direct private equity investments alongside market leading private equity firms globally. NB Alternatives Advisers LLC (the “Investment Manager”), an indirect wholly owned subsidiary of Neuberger Berman Group LLC, is responsible for sourcing, execution and management of NBPE. The vast majority of direct investments are made with no management fee / no carried interest payable to third-party GPs, offering greater fee efficiency than other listed private equity companies. NBPE seeks capital appreciation through growth in net asset value over time while paying a bi-annual dividend.

LEI number: 213800UJH93NH8IOFQ77

About Neuberger

Neuberger was founded in 1939 to do one thing: deliver compelling investment results for our clients over the long term. This remains our singular purpose today, driven by a culture rooted in deep fundamental research, the pursuit of investment insight and continuous innovation on behalf of clients, and facilitated by the free exchange of ideas across the organization.

From offices in 39 cities[1] across 26 countries, Neuberger manages a range of equity, fixed income, private equity and hedge fund strategies on behalf of institutions, advisors and individual investors worldwide. With more than 780[1] investment professionals and over 2,900[1] employees in total, Neuberger has built a diverse team of individuals united in their commitment to client outcomes and investment excellence. Our culture has afforded us enviable retention rates among our senior investment staff and we are proud to have been ranked 1st by Pensions & Investments in their 2025 “Best Places to Work in Money Management” survey, where we have placed 1st in four of the last five years and finished in the top two for 12 consecutive years[2].

As a private, independent, employee-owned investment manager, Neuberger is structurally aligned with the long-term interests of our clients. We have no external parent or public shareholders to serve, nor other lines of business to distract us from our core mission. And with our employees and their families invested alongside our clients—plus 100% of employee deferred cash compensation directly linked to team and firm strategies—we are truly in this together.
For more information, please visit our website: www.nb.com/en/global/who-we-are.

Media Contacts:
US: Soogyung Jordan: Soogyung.Jordan@nb.com
EMEA: Fiona Kehily: Fiona.Kehily@nb.com

[1] Firm data reflects the collective data for the various subsidiaries of Neuberger Berman Group LLC as of 30 June 2026.

[2] Among organizations with over 1,000 employees by Pensions & Investments. For additional information on the criteria for the award, please visit https://www.pionline.com/awards/best-places-to-work-in-money-management/pi-best-places-to-work-2025.

This material is issued on a limited basis through various global subsidiaries and affiliates of Neuberger Berman Group LLC. Please visit www.nb.com/disclosure-global-communications to learn about each company and the legal restrictions and restrictions. The name “Neuberger Berman” and logo are registered service marks of Neuberger Berman Group LLC.

© 2026 Neuberger Berman Group LLC. All rights reserved.

This press release appears as a matter of record only and does not constitute an offer to sell or a solicitation of an offer to purchase any security.

NBPE is established as a closed-end investment company domiciled in Guernsey. NBPE has received the necessary consent of the Guernsey Financial Services Commission. The value of investments may fluctuate. Results achieved in the past are no guarantee of future results. This document is not intended to constitute legal, tax or accounting advice or investment recommendations. Prospective investors are advised to seek expert legal, financial, tax and other professional advice before making any investment decision. Statements contained in this document that are not historical facts are based on current expectations, estimates, projections, opinions and beliefs of NBPE’s investment manager. Such statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon. Additionally, this document contains “forward-looking statements.” Actual events or results or the actual performance of NBPE may differ materially from those reflected or contemplated in such targets or forward-looking statements.

In September 2026, AS Tallink Grupp transported 405,069 passengers, representing a 4.5% increase compared to September 2025. The number of cargo units increased by 10.0% to 23,386 units, while the number of passenger vehicles increased by 0.1% to 56,010 units compared to the same period a year ago.

In the third quarter of the year (July–September) AS Tallink Grupp transported 1,816,174 passengers, representing a 2.8% increase compared to the same period in 2025. The number of transported cargo units increased by 7.8% to 64,980 units and the number of passenger vehicles decreased by 1.1% to 249,100 units compared to the same period a year ago.

AS Tallink Grupp passenger, cargo unit and passenger vehicle volumes for September 2026 and the third quarter of the year were as follows:

  Sept 2026 Sept 2025 Change Q3 2026 Q3 2025 Change
Passengers 405,069 387,482 4.5% 1,816,174 1,766,335 2.8%
Estonia – Finland 281,012 261,530 7.4% 1,183,760 1,166,278 1.5%
Finland – Sweden 92,464 88,933 4.0% 458,650 435,770 5.3%
Estonia – Sweden 31,593 37,019 -14.7% 173,764 164,287 5.8%
             
Cargo Units 23,386 21,269 10.0% 64,980 60,306 7.8%
Estonia – Finland 18,350 15,338 19.6% 51,467 44,388 15.9%
Finland – Sweden 3,578 2,882 24.1% 9,510 7,891 20.5%
Estonia – Sweden 1,458 3,049 -52.2% 4,003 8,027 -50.1%
             
Passenger Vehicles 56,010 55,973 0.1% 249,100 251,751 -1.1%
Estonia – Finland 48,945 48,947 0.0% 203,274 208,228 -2.4%
Finland – Sweden 5,346 4,817 11.0% 32,512 30,107 8.0%
Estonia – Sweden 1,719 2,209 -22.2% 13,314 13,416 -0.8%

ESTONIA – FINLAND
The third quarter results for the Estonia-Finland route reflect the operations of the shuttle vessels MyStar and Megastar and the cruise ferry Victoria I.

FINLAND – SWEDEN
The third quarter results for the Finland-Sweden routes reflect the operations of the Helsinki-Stockholm route (the cruise ferries Silja Serenade and Silja Symphony) and the Turku-Stockholm route (the cruise ferry Baltic Princess). The cruise ferry Baltic Princess did not operate the Turku-Stockholm route for two days in September due to scheduled maintenance works.

ESTONIA – SWEDEN
The third quarter results for the Estonia-Sweden route reflect the operations of the cruise ferries Baltic Queen and Romantika on the Tallinn-Stockholm route, with Romantika operating on the route in July and for three days in August.

A year ago, the Estonia-Sweden routes were operated by the cruise ferry Baltic Queen on the Tallinn-Stockholm route and Superfast IX on the Paldiski-Kapellskär route. Following the commencement of the charter agreement for the passenger vessel Superfast IX on 1 May 2026, operations on the Paldiski-Kapellskär route have been ceased.

Anneli Simm
Investor Relations Manager

AS Tallink Grupp
Sadama 5
10111 Tallinn, Estonia
E-mail anneli.simm@tallink.ee
Phone: +372 5615 7170

Attachment

In September 2026, AS Tallink Grupp transported 405,069 passengers, representing a 4.5% increase compared to September 2025. The number of cargo units increased by 10.0% to 23,386 units, while the number of passenger vehicles increased by 0.1% to 56,010 units compared to the same period a year ago.

In the third quarter of the year (July–September) AS Tallink Grupp transported 1,816,174 passengers, representing a 2.8% increase compared to the same period in 2025. The number of transported cargo units increased by 7.8% to 64,980 units and the number of passenger vehicles decreased by 1.1% to 249,100 units compared to the same period a year ago.

AS Tallink Grupp passenger, cargo unit and passenger vehicle volumes for September 2026 and the third quarter of the year were as follows:

  Sept 2026 Sept 2025 Change Q3 2026 Q3 2025 Change
Passengers 405,069 387,482 4.5% 1,816,174 1,766,335 2.8%
Estonia – Finland 281,012 261,530 7.4% 1,183,760 1,166,278 1.5%
Finland – Sweden 92,464 88,933 4.0% 458,650 435,770 5.3%
Estonia – Sweden 31,593 37,019 -14.7% 173,764 164,287 5.8%
             
Cargo Units 23,386 21,269 10.0% 64,980 60,306 7.8%
Estonia – Finland 18,350 15,338 19.6% 51,467 44,388 15.9%
Finland – Sweden 3,578 2,882 24.1% 9,510 7,891 20.5%
Estonia – Sweden 1,458 3,049 -52.2% 4,003 8,027 -50.1%
             
Passenger Vehicles 56,010 55,973 0.1% 249,100 251,751 -1.1%
Estonia – Finland 48,945 48,947 0.0% 203,274 208,228 -2.4%
Finland – Sweden 5,346 4,817 11.0% 32,512 30,107 8.0%
Estonia – Sweden 1,719 2,209 -22.2% 13,314 13,416 -0.8%

ESTONIA – FINLAND
The third quarter results for the Estonia-Finland route reflect the operations of the shuttle vessels MyStar and Megastar and the cruise ferry Victoria I.

FINLAND – SWEDEN
The third quarter results for the Finland-Sweden routes reflect the operations of the Helsinki-Stockholm route (the cruise ferries Silja Serenade and Silja Symphony) and the Turku-Stockholm route (the cruise ferry Baltic Princess). The cruise ferry Baltic Princess did not operate the Turku-Stockholm route for two days in September due to scheduled maintenance works.

ESTONIA – SWEDEN
The third quarter results for the Estonia-Sweden route reflect the operations of the cruise ferries Baltic Queen and Romantika on the Tallinn-Stockholm route, with Romantika operating on the route in July and for three days in August.

A year ago, the Estonia-Sweden routes were operated by the cruise ferry Baltic Queen on the Tallinn-Stockholm route and Superfast IX on the Paldiski-Kapellskär route. Following the commencement of the charter agreement for the passenger vessel Superfast IX on 1 May 2026, operations on the Paldiski-Kapellskär route have been ceased.

Anneli Simm
Investor Relations Manager

AS Tallink Grupp
Sadama 5
10111 Tallinn, Estonia
E-mail anneli.simm@tallink.ee
Phone: +372 5615 7170

Attachment

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.